2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/2iy5wruuedsh6.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/00yc7rcvua6a7.js","/_next/static/immutable/chunks/37ktb71aq3480.js","/_next/static/immutable/chunks/2d50b-7eu4558.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/2d6noqpp6ehas.js","/_next/static/immutable/chunks/1sx186c93bpzg.js","/_next/static/immutable/chunks/3dc-1n866s65i.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2w1bvggzb0ga8.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T6f6,Tenofovir alafenamide (TAF) is a key component of many fixed-dose combinations used to treat HIV. There are limited data on the pharmacokinetics of plasma tenofovir alafenamide (TAF), tenofovir (TFV), or intracellular tenofovir diphosphate (TFV-DP), among people with HIV (PWH) and tuberculosis (TB) who are taking rifampicin-based TB treatment. Participants in the intervention arm of the INSIGHT trial (NCT04734652) receiving bictegravir/emtricitabine/TAF (BIC/FTC/TAF 50/200/25mg) were enrolled into the semi-intensive pharmacokinetic sub-study. BIC/FTC/TAF was administered twice-daily during rifampicin-based TB treatment (∼24 weeks) and once-daily thereafter. Plasma (TAF/TFV) and dried blood spot samples (TFV-DP) were collected at weeks 4 and 12 (pre-dose, 1, 2, 4, 6, and 8-12h post-dose) during TB treatment and at week 32 (pre-dose, 1, 2, 4, 6-8 and 24-25h post-dose) post-TB treatment. Pharmacokinetic parameters were determined using non-compartmental analysis. Clinical and safety data were collected. Among 43 participants enrolled; median (IQR) age and weight were 35 (30-39) years and 58 (52-65) kg; 77% were male. Geometric least square mean ratios (90% CI) at week 12 (twice-daily TAF) relative to week 32 (once-daily TAF) for TAF AUC0-4, TFV and TFV-DP AUC0-24 were 1.55 (1.13-2.13), 1.24 (1.07-1.44), and 1.32 (1.13-1.53), respectively. At week 24, 95% of participants achieved viral suppression, with no treatment-related serious adverse events or drug discontinuations. Twice-daily TAF was safe and efficacious and achieved similar exposures of intracellular TFV-DP in PWH taking rifampicin for TB compared to once-daily TAF taken alone. These data support the use of TAF in a fixed-dose combination of BIC/FTC/TAF during rifampicin-containing TB treatment.31:T972,Abstract Background Tenofovir alafenamide (TAF) is a key component of many fixed-dose combinations used to treat HIV. There are limited data on the pharmacokinetics of plasma tenofovir alafenamide (TAF), tenofovir (TFV), or intracellular tenofovir diphosphate (TFV-DP), among people with HIV (PWH) and tuberculosis (TB) who are taking rifampicin-based TB treatment. Methods Participants in the intervention arm of the INSIGHT trial (NCT04734652) receiving bictegravir/emtricitabine/TAF (BIC/FTC/TAF 50/200/25mg) were enrolled into the semi-intensive pharmacokinetic sub-study. BIC/FTC/TAF was administered twice-daily during rifampicin-based TB treatment (∼24 weeks) and once-daily thereafter. Plasma (TAF/TFV) and dried blood spot samples (TFV-DP) were collected at weeks 4 and 12 (pre-dose, 1, 2, 4, 6, and 8-12h post-dose) during TB treatment and at week 32 (pre-dose, 1, 2, 4, 6-8 and 24-25h post-dose) post-TB treatment. Pharmacokinetic parameters were determined using non-compartmental analysis. Clinical and safety data were collected. Results Among 43 participants enrolled; median (IQR) age and weight were 35 (30-39) years and 58 (52-65) kg; 77% were male. Geometric least square mean ratios (90% CI) at week 12 (twice-daily TAF) relative to week 32 (once-daily TAF) for TAF AUC0-4, TFV and TFV-DP AUC0-24 were 1.55 (1.13-2.13), 1.24 (1.07-1.44), and 1.32 (1.13-1.53), respectively. At week 24, 95% of participants achieved viral suppression, with no treatment-related serious adverse events or drug discontinuations. Conclusion Twice-daily TAF was safe and efficacious and achieved similar exposures of intracellular TFV-DP in PWH taking rifampicin for TB compared to once-daily TAF taken alone. These data support the use of TAF in a fixed-dose combination of BIC/FTC/TAF during rifampicin-containing TB treatment. 32:Tdd2,To date, clinical trials have been underpowered to assess which antiretrovirals perform best in people with advanced HIV disease. We aimed to investigate the efficacy and safety of an integrase inhibitor-containing versus a boosted protease inhibitor-containing regimen for this population. In this open-label, multicentre, non-inferiority trial in seven European countries (Spain, France, Italy, Germany, Belgium, Ireland, and the UK), therapy-naive adults with advanced HIV disease were randomly allocated (1:1) to receive either bictegravir, emtricitabine, and tenofovir alafenamide (integrase inhibitor group) or darunavir, cobicistat, emtricitabine, and tenofovir alafenamide (boosted protease inhibitor group) for 48 weeks. Randomisation was computer generated in permuted blocks within strata with block sizes of four and stratified by country and baseline CD4 cell count. The primary composite outcome (time to first occurrence of specified virological or clinical events) and its components were evaluated by Kaplan-Meier and Cox regression analyses in both modified intention-to-treat (mITT) and per-protocol populations. The mITT population included all randomly allocated participants who received at least one dose of the study drug, whereas the per-protocol population excluded those who received incorrect treatment. Non-inferiority of the integrase inhibitor-based regimen versus the boosted protease inhibitor-containing regimen was declared if the upper limit of the 95% CI of the hazard ratio (HR) for the primary composite endpoint was less than 1·606, corresponding to a 12% difference in the cumulative probability of the composite primary endpoint. Adverse events, a secondary endpoint, were recorded at eight visits in all participants. This trial is registered with ClinicalTrials.gov, NCT03696160, and is completed. Between May 13, 2019, and June 26, 2023, 222 people were randomly assigned to the integrase inhibitor group and 225 to the boosted protease inhibitor group. Of these 447 recruited participants, 442 (99%) participants with a median CD4 count of 41 cells per μL (IQR 17-79) received at least one dose. 358 (81%) of the 442 treated participants self-reported as male and 84 (19%) female, and 276 (62%) were of White ethnicity, 83 (19%) Black, and 83 (19%) other. In the mITT analysis, the 48-week composite primary outcome event occurred in 49 (22%) of 220 participants in the integrase inhibitor group versus 70 (32%) of 222 participants in the boosted protease inhibitor group (adjusted HR 0·70 [95% CI 0·48-1·00]; non-inferiority shown). The per-protocol analysis gave a similar estimated adjusted HR of 0·69 (0·48-1·00; non-inferiority shown). By mITT, drug-related adverse events (grade ≥2) occurred in 16 (7%) of 220 participants in the integrase inhibitor group versus 32 (14%) of 222 in the boosted protease inhibitor group (p=0·043). The rates of serious adverse events or adverse events leading to study discontinuation did not differ between groups. 12 deaths occurred during the study (nine in the integrase inhibitor group and three in the boosted protease inhibitor group), not related to the study drugs. In people with advanced HIV disease, bictegravir, emtricitabine, and tenofovir alafenamide was shown to be non-inferior to darunavir, cobicistat, emtricitabine, and tenofovir alafenamide and resulted in fewer adverse events, supporting its use as a preferred first-line antiretroviral regimen in this vulnerable population. Gilead Sciences and Janssen Pharmaceuticals.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"tenofovir alafenamide: generic Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on tenofovir alafenamide (generic). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/generic/tenofovir%20alafenamide\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Generics\",\"item\":\"https://www.reachrx.ai/hub/tag/generic\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"tenofovir alafenamide\",\"item\":\"https://www.reachrx.ai/hub/tag/generic/tenofovir%20alafenamide\"}]}}"}}]],["$","$L2f",null,{"title":"tenofovir alafenamide: Research & Clinical Takeaways","description":"Explore research on tenofovir alafenamide (generic) — efficacy, safety, and comparative data.","papers":[{"doi":"10.1056/nejmoa2607973","pmid":"42525925","title":"Phase 3 Trial of Weekly Oral Islatravir–Lenacapavir for HIV-1 Treatment","journal_title":"New England Journal of Medicine","journal_issn":"0028-4793","published_at":"2026-07-29T00:00:00.000Z","url":"https://doi.org/10.1056/nejmoa2607973","source_score":244,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-05T13:22:54.118Z","updated_at":"2026-08-05T13:22:54.118Z","tags":[{"paper_doi":"10.1056/nejmoa2607973","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1056/nejmoa2607973","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1056/nejmoa2607973","tag_type":"brand","value":"Biktarvy","value_numeric":null},{"paper_doi":"10.1056/nejmoa2607973","tag_type":"brand","value":"Sunlenca","value_numeric":null},{"paper_doi":"10.1056/nejmoa2607973","tag_type":"category","value":"Medicine, General & Internal","value_numeric":null},{"paper_doi":"10.1056/nejmoa2607973","tag_type":"condition","value":"HIV-1 Infection","value_numeric":null},{"paper_doi":"10.1056/nejmoa2607973","tag_type":"generic","value":"bictegravir","value_numeric":null},{"paper_doi":"10.1056/nejmoa2607973","tag_type":"generic","value":"emtricitabine","value_numeric":null},{"paper_doi":"10.1056/nejmoa2607973","tag_type":"generic","value":"islatravir","value_numeric":null},{"paper_doi":"10.1056/nejmoa2607973","tag_type":"generic","value":"lenacapavir","value_numeric":null},{"paper_doi":"10.1056/nejmoa2607973","tag_type":"generic","value":"tenofovir alafenamide","value_numeric":null},{"paper_doi":"10.1056/nejmoa2607973","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1056/nejmoa2607973","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1056/nejmoa2607973","tag_type":"modality","value":"Capsid Inhibitor","value_numeric":null},{"paper_doi":"10.1056/nejmoa2607973","tag_type":"modality","value":"Integrase Strand Transfer Inhibitor","value_numeric":null},{"paper_doi":"10.1056/nejmoa2607973","tag_type":"modality","value":"Nucleoside Reverse Transcriptase Translocation Inhibitor","value_numeric":null},{"paper_doi":"10.1056/nejmoa2607973","tag_type":"sample_size","value":"n=607","value_numeric":607},{"paper_doi":"10.1056/nejmoa2607973","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1056/nejmoa2607973","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1056/nejmoa2607973","tag_type":"warning","value":"Brand name for islatravir–lenacapavir combination is not yet confirmed as approved; 'Sunlenca' refers to lenacapavir monotherapy and is used here as a proxy.","value_numeric":null},{"paper_doi":"10.1056/nejmoa2607973","tag_type":"warning","value":"Islatravir is associated with CD4 count declines in prior studies; the modest CD4 difference (−10 vs. −18 cells/µL) warrants monitoring in clinical practice.","value_numeric":null},{"paper_doi":"10.1056/nejmoa2607973","tag_type":"warning","value":"The 96-week secondary endpoint data are not yet reported; long-term durability conclusions cannot be drawn from this abstract alone.","value_numeric":null}],"summaries":{"what_studied":"Phase 3, double-blind, randomized, active-controlled noninferiority trial (ISLEND-1) in 607 virologically suppressed HIV-1 adults across 12 countries, comparing a switch to once-weekly oral islatravir–lenacapavir (ISL/LEN 2 mg/300 mg) versus continuation of once-daily oral bictegravir–emtricitabine–tenofovir alafenamide (B/F/TAF) over 96 weeks (primary endpoint at week 48).","key_result":"At week 48, HIV-1 RNA ≥50 copies/mL occurred in 0 (0%) ISL/LEN vs. 1 (0.3%) B/F/TAF participants (difference −0.3 pp; 95% CI −1.4 to 0.8), meeting the 4 pp noninferiority margin. Viral suppression (<50 copies/mL) was achieved in 93.4% vs. 92.4%, and discontinuations due to adverse events were low and similar (2.0% vs. 1.7%).","limitations":"- Switch trial only (virologically suppressed patients on B/F/TAF); generalizability to treatment-naïve or previously failing patients is unknown.\n- Primary endpoint is at week 48; 96-week durability data not yet reported.\n- Recruited predominantly from existing B/F/TAF users, limiting diversity of prior treatment histories.","practice_takeaway":"Once-weekly oral ISL/LEN is a viable, noninferior alternative to daily B/F/TAF for virologically suppressed adults and may improve adherence through reduced dosing frequency. Clinicians can consider it as a switch option for stable patients seeking a less burdensome regimen."}},{"doi":"10.1093/ofid/ofag471","pmid":null,"title":"VOGUE: Non-Inferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment","journal_title":"Open Forum Infectious Diseases","journal_issn":"2328-8957","published_at":"2026-07-28T00:00:00.000Z","url":"https://doi.org/10.1093/ofid/ofag471","source_score":12,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":false,"crossref":true,"unpaywall":true},"created_at":"2026-07-31T13:37:05.241Z","updated_at":"2026-07-31T13:37:05.241Z","tags":[{"paper_doi":"10.1093/ofid/ofag471","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag471","tag_type":"brand","value":"Biktarvy","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag471","tag_type":"brand","value":"Dovato","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag471","tag_type":"category","value":"Immunology","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag471","tag_type":"condition","value":"HIV-1 Infection","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag471","tag_type":"generic","value":"bictegravir","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag471","tag_type":"generic","value":"bictegravir/emtricitabine/tenofovir alafenamide","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag471","tag_type":"generic","value":"dolutegravir","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag471","tag_type":"generic","value":"dolutegravir/lamivudine","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag471","tag_type":"generic","value":"emtricitabine","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag471","tag_type":"generic","value":"lamivudine","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag471","tag_type":"generic","value":"tenofovir alafenamide","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag471","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag471","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag471","tag_type":"modality","value":"Antiretroviral Therapy","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag471","tag_type":"modality","value":"Integrase Strand Transfer Inhibitor","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag471","tag_type":"sample_size","value":"n=509","value_numeric":509},{"paper_doi":"10.1093/ofid/ofag471","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag471","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag471","tag_type":"warning","value":"Baseline resistance testing was not completed before treatment initiation, which may have influenced virologic withdrawal rates in a real-world context.","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag471","tag_type":"warning","value":"Open-label design is a notable methodological limitation; blinding was not feasible given the different pill counts and regimens. Clinicians should interpret the 3% absolute difference cautiously, as the confidence interval nearly touches the non-inferiority margin of -10%.","value_numeric":null},{"paper_doi":"10.1093/ofid/ofag471","tag_type":"warning","value":"The brand name for dolutegravir/lamivudine (Dovato) is inferred from the drug combination; the paper does not explicitly state the brand name.","value_numeric":null}],"summaries":{"what_studied":"Phase 3b randomized open-label non-inferiority trial comparing the 2-drug regimen dolutegravir/lamivudine (DTG/3TC) vs. the 3-drug regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as first-line ART in 509 treatment-naive adults with HIV-1, including those with high viral loads (≥100,000 copies/mL, 47%) and low CD4+ counts (<200 cells/mm³, 16%), through 48 weeks.","key_result":"DTG/3TC was non-inferior to BIC/FTC/TAF: HIV-1 RNA <50 copies/mL at Week 48 was achieved in 89% vs. 92%, respectively (adjusted difference −3% [95% CI −8%, 2%]). Median time to virologic suppression was 4.1 weeks in both arms. Confirmed virologic withdrawals were equal (n=7 each), and no treatment-emergent resistance was detected in either group through Week 48.","limitations":"- Open-label design may introduce outcome assessment bias.\n- 48-week follow-up may not capture longer-term resistance emergence or durability differences.\n- Resistance testing results were unavailable at treatment initiation, so some participants may have had undetected baseline resistance.","practice_takeaway":"DTG/3TC (a 2-drug regimen) can be offered as initial ART across a broad range of patients, including those with high viral loads or low CD4+ counts, without sacrificing virologic efficacy compared to BIC/FTC/TAF. The absence of treatment-emergent resistance through 48 weeks supports its use even before resistance testing results are available."}},{"doi":"10.1080/14787210.2026.2690003","pmid":"42298392","title":"Hepatitis B in pregnancy and breastfeeding: current approaches to prophylaxis and treatment","journal_title":"Expert Review of Anti-infective Therapy","journal_issn":"1478-7210","published_at":"2026-06-15T00:00:00.000Z","url":"https://doi.org/10.1080/14787210.2026.2690003","source_score":13,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-20T13:24:54.616Z","updated_at":"2026-06-20T13:24:54.616Z","tags":[{"paper_doi":"10.1080/14787210.2026.2690003","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2690003","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2690003","tag_type":"condition","value":"Chronic Hepatitis B","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2690003","tag_type":"condition","value":"Mother-to-Child Transmission of Hepatitis B","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2690003","tag_type":"generic","value":"tenofovir alafenamide","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2690003","tag_type":"generic","value":"tenofovir disoproxil fumarate","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2690003","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2690003","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2690003","tag_type":"modality","value":"Hepatitis B Immunoglobulin","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2690003","tag_type":"modality","value":"Hepatitis B Vaccine","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2690003","tag_type":"modality","value":"Nucleotide Reverse Transcriptase Inhibitor","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2690003","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2690003","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2690003","tag_type":"warning","value":"Full text was not accessible; structured data extracted from abstract, article highlights, and publisher page only — detailed efficacy numbers and study quality assessments could not be verified.","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2690003","tag_type":"warning","value":"One lead author discloses an institutional research grant from Gilead Sciences, which markets tenofovir-based therapies discussed favorably in this review; readers should weigh potential influence on conclusions.","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2690003","tag_type":"warning","value":"Study design tagged as 'Narrative Review' based on article type labeling; no systematic search methodology or PRISMA reporting was confirmed in the available text.","value_numeric":null}],"summaries":{"what_studied":"This review evaluates current strategies for preventing and managing hepatitis B virus (HBV) mother-to-child transmission (MTCT), covering maternal antiviral prophylaxis with TDF and TAF, HBIG-free approaches, novel vaccines, postpartum flare management, and breastfeeding safety during antiviral therapy.","key_result":"Maternal antiviral prophylaxis (TDF or TAF) is effective and safe for reducing MTCT, particularly when maternal HBV DNA exceeds 200,000 IU/mL; HBIG-free strategies are viable; and breastfeeding is considered safe during TDF or TAF therapy. Vaccination plus HBIG reduces MTCT but faces cost and access barriers in resource-limited settings.","limitations":"- Full text was not available; conclusions are drawn from the abstract, highlights, and publisher page only.\n- No original patient data are presented — this is a narrative review without meta-analytic pooling or quality assessment of included studies.\n- Conflict of interest noted: one author receives institutional research funding from Gilead Sciences, a manufacturer of tenofovir-based therapies.","practice_takeaway":"Offer antiviral prophylaxis (TDF or TAF) to pregnant women with HBV DNA >200,000 IU/mL, in addition to infant immunoprophylaxis. Breastfeeding need not be withheld in mothers maintained on TDF or TAF."}},{"doi":"10.1093/cid/ciaf732","pmid":"41467354","title":"Pharmacokinetics of Twice-Daily Tenofovir Alafenamide In Adults with HIV-Associated TB on BIC/FTC/TAF and Rifampicin","journal_title":"Clinical Infectious Diseases","journal_issn":"1058-4838","published_at":"2025-12-30T00:00:00.000Z","url":"https://doi.org/10.1093/cid/ciaf732","source_score":8,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-03","doi":"10.1093/cid/ciaf732","days":"7","issn":"1058-4838","rank":"10","field":"Clinical Medicine","score":"8","category":"Infectious Diseases","categories":["Infectious Diseases"],"_categories":["Infectious Diseases"]},"pubmed":{"doi":"10.1093/cid/ciaf732","title":"Pharmacokinetics of Twice-Daily Tenofovir Alafenamide In Adults with HIV-Associated TB on BIC/FTC/TAF and Rifampicin.","journal":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","methods":"","results":"Among 43 participants enrolled; median (IQR) age and weight were 35 (30-39) years and 58 (52-65) kg; 77% were male. Geometric least square mean ratios (90% CI) at week 12 (twice-daily TAF) relative to week 32 (once-daily TAF) for TAF AUC0-4, TFV and TFV-DP AUC0-24 were 1.55 (1.13-2.13), 1.24 (1.07-1.44), and 1.32 (1.13-1.53), respectively. At week 24, 95% of participants achieved viral suppression, with no treatment-related serious adverse events or drug discontinuations.","abstract":"$30","keywords":["HIV","Pharmacokinetics","Rifampicin","Tenofovir alafenamide","Tuberculosis","drug-interactions"],"pubmed_id":"41467354","conclusions":"Twice-daily TAF was safe and efficacious and achieved similar exposures of intracellular TFV-DP in PWH taking rifampicin for TB compared to once-daily TAF taken alone. These data support the use of TAF in a fixed-dose combination of BIC/FTC/TAF during rifampicin-containing TB treatment.","publication_date":"2025-12-30T00:00:00"},"crossref":{"DOI":"10.1093/cid/ciaf732","URL":"https://doi.org/10.1093/cid/ciaf732","ISSN":["1058-4838","1537-6591"],"link":[{"URL":"https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaf732/66151332/ciaf732.pdf","content-type":"application/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaf732/66151332/ciaf732.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Pharmacokinetics of Twice-Daily Tenofovir Alafenamide In Adults with HIV-Associated TB on BIC/FTC/TAF and Rifampicin"],"author":[{"given":"Emmanuella Chinonso","family":"Osuala","sequence":"first","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu-Natal , Durban ,"}]},{"given":"Ivan Nicholas","family":"Nkuhairwe","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Cape Town ,"}]},{"given":"Marothi Peter","family":"Letsoalo","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu-Natal , Durban ,"}]},{"given":"Kogieleum","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu-Natal , Durban ,"},{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), South African Medical Research Council (SAMRC)-CAPRISA-TB-HIV Pathogenesis and Treatment Research Unit, University of KwaZulu-Natal Nelson R Mandela School of Medicine , Durban ,"}]},{"given":"Rubeshan","family":"Perumal","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu-Natal , Durban ,"},{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), South African Medical Research Council (SAMRC)-CAPRISA-TB-HIV Pathogenesis and Treatment Research Unit, University of KwaZulu-Natal Nelson R Mandela School of Medicine , Durban ,"}]},{"given":"James F","family":"Rooney","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Foster City, CA ,"}]},{"given":"Lubbe","family":"Wiesner","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Cape Town ,"}]},{"given":"Roeland E","family":"Wasmann","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Cape Town ,"}]},{"given":"Paolo","family":"Denti","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Cape Town ,"}]},{"given":"Kelly E","family":"Dooley","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center , Nashville, Tennessee ,"}]},{"given":"Anushka","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, University of KwaZulu-Natal , Durban ,"},{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), South African Medical Research Council (SAMRC)-CAPRISA-TB-HIV Pathogenesis and Treatment Research Unit, University of KwaZulu-Natal Nelson R Mandela School of Medicine , Durban ,"}]},{"given":null,"family":null,"sequence":"additional","affiliation":[]},{"given":"Anushka","family":"Naidoo","sequence":"additional","affiliation":[]},{"given":"Kelly E","family":"Dooley","sequence":"additional","affiliation":[]},{"given":"Kogieleum","family":"Naidoo","sequence":"additional","affiliation":[]},{"given":"Gillian","family":"Dorse","sequence":"additional","affiliation":[]},{"given":"Rubeshan","family":"Perumal","sequence":"additional","affiliation":[]},{"given":"Resha","family":"Boodhram","sequence":"additional","affiliation":[]},{"given":"Busisiwe","family":"Ntsalaze","sequence":"additional","affiliation":[]},{"given":"Samiksha","family":"Byroo","sequence":"additional","affiliation":[]},{"given":"Ellisha","family":"Francis","sequence":"additional","affiliation":[]},{"given":"Anokhee","family":"Leela","sequence":"additional","affiliation":[]},{"given":"Rosemary","family":"Gray","sequence":"additional","affiliation":[]},{"given":"Bhavna","family":"Maharaj","sequence":"additional","affiliation":[]},{"given":"Nompumelelo","family":"Zungu","sequence":"additional","affiliation":[]},{"given":"Phindile","family":"Msomi","sequence":"additional","affiliation":[]},{"given":"Claudia","family":"Shozi","sequence":"additional","affiliation":[]},{"given":"Radhamoney","family":"Narasimmulu","sequence":"additional","affiliation":[]},{"given":"Nokuzola","family":"Cwazibe","sequence":"additional","affiliation":[]},{"given":"Rajesperi","family":"Venter","sequence":"additional","affiliation":[]},{"given":"Saras","family":"Pather","sequence":"additional","affiliation":[]},{"given":"Nokwanda","family":"Depargo","sequence":"additional","affiliation":[]},{"given":"Silindile","family":"Tenza","sequence":"additional","affiliation":[]},{"given":"Patience","family":"Mbatha","sequence":"additional","affiliation":[]},{"given":"Marothi","family":"Letsoalo","sequence":"additional","affiliation":[]},{"given":"Mxolisi","family":"Mahlangu","sequence":"additional","affiliation":[]},{"given":"Natasha","family":"Samsunder","sequence":"additional","affiliation":[]},{"given":"Zanele","family":"Mchunu","sequence":"additional","affiliation":[]},{"given":"Avanthi","family":"Moodley-Reddy","sequence":"additional","affiliation":[]},{"given":"Lungile","family":"Maphumulo","sequence":"additional","affiliation":[]},{"given":"Adejumoke","family":"Abiose","sequence":"additional","affiliation":[]},{"given":"Emmanuella","family":"Chinonso Osuala","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2025,12,30]]},"member":"286","prefix":"10.1093","source":"Crossref","volume":null,"created":{"date-time":"2025-12-29T12:30:21Z","timestamp":1767011421000,"date-parts":[[2025,12,29]]},"indexed":{"date-time":"2025-12-30T10:01:32Z","timestamp":1767088892355,"date-parts":[[2025,12,30]]},"license":[{"URL":"https://creativecommons.org/licenses/by-nc-nd/4.0/","start":{"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000,"date-parts":[[2025,12,30]]},"delay-in-days":0,"content-version":"am"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaf732/8407225"}},"subtitle":[],"deposited":{"date-time":"2025-12-30T09:59:12Z","timestamp":1767088752000,"date-parts":[[2025,12,30]]},"issn-type":[{"type":"print","value":"1058-4838"},{"type":"electronic","value":"1537-6591"}],"published":{"date-parts":[[2025,12,30]]},"publisher":"Oxford University Press (OUP)","reference":null,"short-title":[],"article-number":"ciaf732","content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["Clinical Infectious Diseases"],"reference-count":0,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,30]]},"references-count":0,"short-container-title":[],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1093/cid/ciaf732","is_oa":true,"title":"Pharmacokinetics of Twice-Daily Tenofovir Alafenamide In Adults with HIV-Associated TB on BIC/FTC/TAF and Rifampicin","updated":"2026-01-01T00:56:08+00:00","published_date":"2025-12-29","best_oa_location":{"url":"https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaf732/66151332/ciaf732.pdf","pmh_id":null,"url_for_pdf":"https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaf732/66151332/ciaf732.pdf","url_for_landing_page":"https://doi.org/10.1093/cid/ciaf732"}}},"created_at":"2026-01-11T11:19:33.869Z","updated_at":"2026-01-11T11:19:33.869Z","tags":[{"paper_doi":"10.1093/cid/ciaf732","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf732","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf732","tag_type":"condition","value":"HIV Infection","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf732","tag_type":"condition","value":"Tuberculosis","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf732","tag_type":"generic","value":"bictegravir","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf732","tag_type":"generic","value":"emtricitabine","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf732","tag_type":"generic","value":"tenofovir alafenamide","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf732","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf732","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf732","tag_type":"modality","value":"Antiretroviral Therapy","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf732","tag_type":"sample_size","value":"n=43","value_numeric":43},{"paper_doi":"10.1093/cid/ciaf732","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf732","tag_type":"study_design","value":"Prospective Cohort","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf732","tag_type":"warning","value":"Comparisons are across different weeks on vs off rifampicin, not randomized.","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf732","tag_type":"warning","value":"Design classification is approximate; this is a single-arm pharmacokinetic sub-study with within-participant timepoint comparisons.","value_numeric":null},{"paper_doi":"10.1093/cid/ciaf732","tag_type":"warning","value":"Generalizability may be limited by the small, male-predominant cohort.","value_numeric":null}],"summaries":{"what_studied":"A semi‑intensive pharmacokinetic sub‑study in adults with HIV and tuberculosis on rifampicin evaluated BIC/FTC/TAF 50/200/25 mg given twice daily during ~24 weeks of TB therapy and once daily afterward, comparing week 12 (BID, on rifampicin) with week 32 (QD, off rifampicin). Plasma TAF/TFV and dried blood spot TFV‑DP were sampled at weeks 4, 12, and 32; n=43.","key_result":"Geometric least squares mean ratios (week 12 BID vs week 32 QD) were: TAF AUC0‑4 1.55 (90% CI 1.13–2.13), TFV AUC0‑24 1.24 (1.07–1.44), and TFV‑DP AUC0‑24 1.32 (1.13–1.53). By week 24, 95% achieved viral suppression, with no treatment‑related serious adverse events or drug discontinuations.","limitations":"Single‑arm PK sub‑study with within‑participant comparisons across timepoints rather than a randomized control. Modest sample size (n=43) with 77% male may limit generalizability.","practice_takeaway":"Twice‑daily BIC/FTC/TAF during rifampicin‑based TB treatment achieved intracellular TFV‑DP exposure comparable to once‑daily dosing off rifampicin and high virologic suppression without serious toxicity, supporting use of TAF within BIC/FTC/TAF during rifampicin therapy."}},{"doi":"10.1016/s1473-3099(25)00681-4","pmid":"41344354","title":"Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial","journal_title":"The Lancet Infectious Diseases","journal_issn":"1473-3099","published_at":"2025-12-05T00:00:00.000Z","url":"https://doi.org/10.1016/s1473-3099(25)00681-4","source_score":40,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-12-01","doi":"10.1016/s1473-3099(25)00681-4","days":"7","issn":"1473-3099","rank":"4","field":"Clinical Medicine","score":"40","category":"Infectious Diseases","categories":["Infectious Diseases"],"_categories":["Infectious Diseases"]},"pubmed":{"doi":"10.1016/S1473-3099(25)00681-4","title":"Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial.","journal":"The Lancet. Infectious diseases","methods":"","results":"","abstract":"$32","keywords":[],"pubmed_id":"41344354","conclusions":"","publication_date":"2025-12-05T00:00:00"},"crossref":{"DOI":"10.1016/s1473-3099(25)00681-4","URL":"https://doi.org/10.1016/s1473-3099(25)00681-4","ISSN":["1473-3099"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S1473309925006814?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S1473309925006814?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial"],"author":[{"given":"Georg M N","family":"Behrens","sequence":"first","affiliation":[]},{"given":"Lambert","family":"Assoumou","sequence":"additional","affiliation":[]},{"given":"Geoffroy","family":"Liegeon","sequence":"additional","affiliation":[]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[]},{"given":"Rafael","family":"Micán","sequence":"additional","affiliation":[]},{"given":"Francesco G","family":"Genderini","sequence":"additional","affiliation":[]},{"given":"Frank A","family":"Post","sequence":"additional","affiliation":[]},{"given":"Jürgen K","family":"Rockstroh","sequence":"additional","affiliation":[]},{"given":"Lisa","family":"Hamzah","sequence":"additional","affiliation":[]},{"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[]},{"given":"Adrian","family":"Curran","sequence":"additional","affiliation":[]},{"given":"Montserrat","family":"Laguno","sequence":"additional","affiliation":[]},{"given":"Carl","family":"Fletcher","sequence":"additional","affiliation":[]},{"given":"Jack","family":"Moody","sequence":"additional","affiliation":[]},{"given":"Anton","family":"Pozniak","sequence":"additional","affiliation":[]},{"given":"Georg M N","family":"Behrens","sequence":"additional","affiliation":[]},{"given":"Brenda","family":"Crabtree","sequence":"additional","affiliation":[]},{"given":"Nikos","family":"Dedes","sequence":"additional","affiliation":[]},{"given":"Carlo","family":"Giaquinto","sequence":"additional","affiliation":[]},{"given":"Beatriz","family":"Grinsztejn","sequence":"additional","affiliation":[]},{"given":"Esteban","family":"Martinez","sequence":"additional","affiliation":[]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[]},{"given":"Anton","family":"Pozniak","sequence":"additional","affiliation":[]},{"given":"Jürgen K","family":"Rockstroh","sequence":"additional","affiliation":[]},{"given":"Francois","family":"Venter","sequence":"additional","affiliation":[]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[]},{"given":"Cristina Gómez","family":"Ayerbe","sequence":"additional","affiliation":[]},{"given":"Georg M N","family":"Behrens","sequence":"additional","affiliation":[]},{"given":"Phil","family":"Bright","sequence":"additional","affiliation":[]},{"given":"Mar Masia","family":"Canuto","sequence":"additional","affiliation":[]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[]},{"given":"Aoife","family":"Cotter","sequence":"additional","affiliation":[]},{"given":"Alberto","family":"Díaz De Santiago","sequence":"additional","affiliation":[]},{"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[]},{"given":"Adriàn Curran","family":"Fabregas","sequence":"additional","affiliation":[]},{"given":"Julie","family":"Fox","sequence":"additional","affiliation":[]},{"given":"Lucio Jesus","family":"Garcia-Fraile","sequence":"additional","affiliation":[]},{"given":"Francesco Giovanni","family":"Genderini","sequence":"additional","affiliation":[]},{"given":"Andrea","family":"Giacomelli","sequence":"additional","affiliation":[]},{"given":"Juan","family":"Gonzalez","sequence":"additional","affiliation":[]},{"given":"Giovanni","family":"Guaraldi","sequence":"additional","affiliation":[]},{"given":"Lisa","family":"Hamzah","sequence":"additional","affiliation":[]},{"given":"Elbushra","family":"Herieka","sequence":"additional","affiliation":[]},{"given":"Guillen Sirera","family":"Jiménez","sequence":"additional","affiliation":[]},{"given":"Margaret Anne","family":"Johnson","sequence":"additional","affiliation":[]},{"given":"Christine","family":"Katlama","sequence":"additional","affiliation":[]},{"given":"Stephen","family":"Kegg","sequence":"additional","affiliation":[]},{"given":"Chris","family":"Kenyon","sequence":"additional","affiliation":[]},{"given":"Hernando","family":"Knobel","sequence":"additional","affiliation":[]},{"given":"Karine","family":"Lacombe","sequence":"additional","affiliation":[]},{"given":"Montserrat","family":"Laguno","sequence":"additional","affiliation":[]},{"given":"Clara","family":"Lehmann","sequence":"additional","affiliation":[]},{"given":"Pierre","family":"Leroy","sequence":"additional","affiliation":[]},{"given":"Alain","family":"Makinson","sequence":"additional","affiliation":[]},{"given":"Patrick","family":"Mallon","sequence":"additional","affiliation":[]},{"given":"Giulia","family":"Marchetti","sequence":"additional","affiliation":[]},{"given":"Rob","family":"Miller","sequence":"additional","affiliation":[]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[]},{"given":"Roya","family":"Movahedi","sequence":"additional","affiliation":[]},{"given":"Chloe Meave","family":"Orkin","sequence":"additional","affiliation":[]},{"given":"Federico Pulido","family":"Ortega","sequence":"additional","affiliation":[]},{"given":"Jose Luis Casado","family":"Osorio","sequence":"additional","affiliation":[]},{"given":"Patrick","family":"Philibert","sequence":"additional","affiliation":[]},{"given":"Joaquín","family":"Portilla","sequence":"additional","affiliation":[]},{"given":"Frank Alexander","family":"Post","sequence":"additional","affiliation":[]},{"given":"Francois","family":"Raffi","sequence":"additional","affiliation":[]},{"given":"Jose Ramon Blanco","family":"Ramos","sequence":"additional","affiliation":[]},{"given":"Iain","family":"Reeves","sequence":"additional","affiliation":[]},{"given":"Jürgen","family":"Rockstroh","sequence":"additional","affiliation":[]},{"given":"Karen","family":"Rogstad","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Saumoy","sequence":"additional","affiliation":[]},{"given":"Guido","family":"Schäfer","sequence":"additional","affiliation":[]},{"given":"Sarah","family":"Schoeman","sequence":"additional","affiliation":[]},{"given":"Christoph D","family":"Spinner","sequence":"additional","affiliation":[]},{"given":"Christoph","family":"Stephan","sequence":"additional","affiliation":[]},{"given":"Janina","family":"Trauth","sequence":"additional","affiliation":[]},{"given":"Andrew Peter","family":"Ustianowski","sequence":"additional","affiliation":[]},{"given":"Linos","family":"Vandekerckhove","sequence":"additional","affiliation":[]},{"given":"Alan","family":"Winston","sequence":"additional","affiliation":[]}],"funder":[{"id":[{"id":"10.13039/100008897","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100008897","name":"Janssen Pharmaceuticals Inc","doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100005564","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2025,12]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":null,"created":{"date-time":"2025-12-01T11:19:48Z","timestamp":1764587988000,"date-parts":[[2025,12,1]]},"indexed":{"date-time":"2025-12-03T20:18:43Z","timestamp":1764793123316,"date-parts":[[2025,12,3]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000,"date-parts":[[2025,12,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000,"date-parts":[[2025,12,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000,"date-parts":[[2025,11,5]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S1473309925006814"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial"},{"name":"journaltitle","label":"Journal Title","value":"The Lancet Infectious Diseases"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/S1473-3099(25)00681-4"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2025 The Author(s). Published by Elsevier Ltd."}],"deposited":{"date-time":"2025-12-03T20:15:55Z","timestamp":1764792955000,"date-parts":[[2025,12,3]]},"issn-type":[{"type":"print","value":"1473-3099"}],"published":{"date-parts":[[2025,12]]},"publisher":"Elsevier BV","reference":[{"DOI":"10.1111/j.1468-1293.2010.00857.x","key":"10.1016/S1473-3099(25)00681-4_bib2","year":"2011","issue":null,"author":"Antinori","volume":"12","first-page":"61","unstructured":null,"article-title":"Late presentation of HIV infection: a consensus definition","journal-title":"HIV Med","doi-asserted-by":"crossref"},{"DOI":"10.1002/jia2.26415","key":"10.1016/S1473-3099(25)00681-4_bib3","year":"2025","issue":null,"author":"Ford","volume":"28","first-page":null,"unstructured":null,"article-title":"Global prevalence of advanced HIV disease in healthcare settings: a rapid review","journal-title":"J Int AIDS Soc","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2352-3018(22)00067-4","key":"10.1016/S1473-3099(25)00681-4_bib4","year":"2022","issue":"suppl 1","author":"Lee","volume":"9","first-page":"S2","unstructured":null,"article-title":"Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004–18: a cohort study","journal-title":"Lancet HIV","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2214-109X(24)00538-2","key":"10.1016/S1473-3099(25)00681-4_bib5","year":"2025","issue":null,"author":"Stelzle","volume":"13","first-page":"e437","unstructured":null,"article-title":"Prevalence of advanced HIV disease in sub-Saharan Africa: a multi-country analysis of nationally representative household surveys","journal-title":"Lancet Glob Health","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ijid.2024.106995","key":"10.1016/S1473-3099(25)00681-4_bib7","year":"2024","issue":null,"author":"Mondi","volume":"142","first-page":null,"unstructured":null,"article-title":"Persistent poor clinical outcomes of people living with HIV presenting with AIDS and late HIV diagnosis—results from the ICONA cohort in Italy, 2009–2022","journal-title":"Int J Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMp2313777","key":"10.1016/S1473-3099(25)00681-4_bib8","year":"2024","issue":null,"author":"Ford","volume":"390","first-page":"487","unstructured":null,"article-title":"Advanced HIV as a neglected disease","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(18)32462-0","key":"10.1016/S1473-3099(25)00681-4_bib9","year":"2019","issue":null,"author":"Cahn","volume":"393","first-page":"143","unstructured":null,"article-title":null,"journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(17)32299-7","key":"10.1016/S1473-3099(25)00681-4_bib10","year":"2017","issue":null,"author":"Gallant","volume":"390","first-page":"2063","unstructured":null,"article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380–1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(17)32340-1","key":"10.1016/S1473-3099(25)00681-4_bib11","year":"2017","issue":null,"author":"Sax","volume":"390","first-page":"2073","unstructured":null,"article-title":null,"journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1093/cid/ciaf415","key":"10.1016/S1473-3099(25)00681-4_bib12","year":"2025","issue":null,"author":"Figueroa","volume":null,"first-page":null,"unstructured":null,"article-title":"Efficacy and safety of dual therapy with dolutegravir/lamivudine in treatment-naive persons with CD4 counts <200/mm3: 48-week results of the DOLCE study","journal-title":"Clin Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pone.0222650","key":"10.1016/S1473-3099(25)00681-4_bib13","year":"2019","issue":null,"author":"Mussini","volume":"14","first-page":null,"unstructured":null,"article-title":"A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naive patients with CD4<200 cells/uL (the PRADAR study)","journal-title":"PLoS One","doi-asserted-by":"crossref"},{"DOI":"10.1093/jac/dkw103","key":"10.1016/S1473-3099(25)00681-4_bib14","year":"2016","issue":null,"author":"Slama","volume":"71","first-page":"2252","unstructured":null,"article-title":null,"journal-title":"J Antimicrob Chemother","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1014181","key":"10.1016/S1473-3099(25)00681-4_bib15","year":"2011","issue":null,"author":"Abdool Karim","volume":"365","first-page":"1492","unstructured":null,"article-title":"Integration of antiretroviral therapy with tuberculosis treatment","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1013911","key":"10.1016/S1473-3099(25)00681-4_bib16","year":"2011","issue":null,"author":"Blanc","volume":"365","first-page":"1471","unstructured":null,"article-title":"Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pone.0005575","key":"10.1016/S1473-3099(25)00681-4_bib17","year":"2009","issue":null,"author":"Zolopa","volume":"4","first-page":null,"unstructured":null,"article-title":"Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial","journal-title":"PLoS One","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pmed.1002706","key":"10.1016/S1473-3099(25)00681-4_bib18","year":"2018","issue":null,"author":"Kityo","volume":"15","first-page":null,"unstructured":null,"article-title":"Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: a randomised controlled trial","journal-title":"PLoS Med","doi-asserted-by":"crossref"},{"DOI":"10.7326/M19-2133","key":"10.1016/S1473-3099(25)00681-4_bib19","year":"2020","issue":null,"author":"Lévy","volume":"172","first-page":"297","unstructured":null,"article-title":"Addition of maraviroc versus placebo to standard antiretroviral therapy for initial treatment of advanced HIV infection: a randomized trial","journal-title":"Ann Intern Med","doi-asserted-by":"crossref"},{"DOI":"10.1093/jac/dkac361","key":"10.1016/S1473-3099(25)00681-4_bib21","year":"2022","issue":null,"author":"Burgos","volume":"78","first-page":"108","unstructured":null,"article-title":"Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimens","journal-title":"J Antimicrob Chemother","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ijantimicag.2023.107016","key":"10.1016/S1473-3099(25)00681-4_bib22","year":"2024","issue":null,"author":"Corona","volume":"63","first-page":null,"unstructured":null,"article-title":"Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters","journal-title":"Int J Antimicrob Agents","doi-asserted-by":"crossref"},{"DOI":"10.3390/v15051123","key":"10.1016/S1473-3099(25)00681-4_bib23","year":"2023","issue":null,"author":"Fabbiani","volume":"15","first-page":null,"unstructured":null,"article-title":"Efficacy and durability of dolutegravir- or darunavir-based regimens in ART-naive AIDS- or late-presenting HIV-infected patients","journal-title":"Viruses","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ijid.2025.107883","key":"10.1016/S1473-3099(25)00681-4_bib24","year":"2025","issue":null,"author":"Gagliardini","volume":"155","first-page":null,"unstructured":null,"article-title":"Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: a trial emulation","journal-title":"Int J Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1093/jac/dkz237","key":"10.1016/S1473-3099(25)00681-4_bib25","year":"2019","issue":null,"author":"Gianotti","volume":"74","first-page":"2732","unstructured":null,"article-title":"Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL","journal-title":"J Antimicrob Chemother","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S1473-3099(25)00681-4_bib26","year":"2008","issue":null,"author":"Schneider","volume":"57","first-page":"1","unstructured":null,"article-title":"Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years—United States, 2008","journal-title":"MMWR Recomm Rep","doi-asserted-by":null},{"DOI":"10.1056/NEJMoa1312884","key":"10.1016/S1473-3099(25)00681-4_bib27","year":"2014","issue":null,"author":"Boulware","volume":"370","first-page":"2487","unstructured":null,"article-title":"Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1013607","key":"10.1016/S1473-3099(25)00681-4_bib28","year":"2011","issue":null,"author":"Havlir","volume":"365","first-page":"1482","unstructured":null,"article-title":"Timing of antiretroviral therapy for HIV-1 infection and tuberculosis","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1615822","key":"10.1016/S1473-3099(25)00681-4_bib29","year":"2017","issue":null,"author":"Hakim","volume":"377","first-page":"233","unstructured":null,"article-title":"Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1111/hiv.13467","key":"10.1016/S1473-3099(25)00681-4_bib30","year":"2023","issue":null,"author":"Mounzer","volume":"24","first-page":"716","unstructured":null,"article-title":"Immune response to ART initiation in advanced HIV infection","journal-title":"HIV Med","doi-asserted-by":"crossref"},{"DOI":"10.3389/fmicb.2022.846943","key":"10.1016/S1473-3099(25)00681-4_bib31","year":"2022","issue":null,"author":"Miranda","volume":"13","first-page":null,"unstructured":null,"article-title":"Trends of transmitted and acquired drug resistance in Europe from 1981 to 2019: a comparison between the populations of late presenters and non-late presenters","journal-title":"Front Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(14)60084-2","key":"10.1016/S1473-3099(25)00681-4_bib32","year":"2014","issue":null,"author":"Clotet","volume":"383","first-page":"2222","unstructured":null,"article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1093/cid/ciae191","key":"10.1016/S1473-3099(25)00681-4_bib33","year":"2024","issue":null,"author":"Wohl","volume":"79","first-page":"999","unstructured":null,"article-title":"Antiretrovirals and weight change: weighing the evidence","journal-title":"Clin Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.eclinm.2019.11.003","key":"10.1016/S1473-3099(25)00681-4_bib34","year":"2019","issue":null,"author":"Wijting","volume":"17","first-page":null,"unstructured":null,"article-title":"Immune reconstitution inflammatory syndrome in HIV infected late presenters starting integrase inhibitor containing antiretroviral therapy","journal-title":"EClinicalMedicine","doi-asserted-by":"crossref"},{"DOI":"10.1097/COH.0000000000000445","key":"10.1016/S1473-3099(25)00681-4_bib35","year":"2018","issue":null,"author":"Hill","volume":"13","first-page":"102","unstructured":null,"article-title":"Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials","journal-title":"Curr Opin HIV AIDS","doi-asserted-by":"crossref"}],"updated-by":[{"DOI":"10.1016/s1473-3099(25)00745-5","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000,"date-parts":[[2025,12,3]]}}],"short-title":[],"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S1473309925006814"],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["The Lancet Infectious Diseases"],"published-print":{"date-parts":[[2025,12]]},"reference-count":32,"published-online":null,"references-count":32,"short-container-title":["The Lancet Infectious Diseases"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1016/s1473-3099(25)00681-4","is_oa":true,"title":"Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial","updated":"2025-12-01T22:21:40+00:00","published_date":"2025-12-01","best_oa_location":{"url":"https://doi.org/10.1016/s1473-3099(25)00681-4","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1016/s1473-3099(25)00681-4"}}},"created_at":"2025-12-08T12:24:58.509Z","updated_at":"2025-12-08T12:24:58.509Z","tags":[{"paper_doi":"10.1016/s1473-3099(25)00681-4","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00681-4","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00681-4","tag_type":"condition","value":"Advanced HIV Disease","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00681-4","tag_type":"generic","value":"bictegravir","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00681-4","tag_type":"generic","value":"cobicistat","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00681-4","tag_type":"generic","value":"darunavir","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00681-4","tag_type":"generic","value":"emtricitabine","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00681-4","tag_type":"generic","value":"tenofovir alafenamide","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00681-4","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00681-4","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00681-4","tag_type":"modality","value":"Integrase Inhibitor","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00681-4","tag_type":"modality","value":"Protease Inhibitor","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00681-4","tag_type":"sample_size","value":"n=442","value_numeric":442},{"paper_doi":"10.1016/s1473-3099(25)00681-4","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00681-4","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00681-4","tag_type":"warning","value":"Composite endpoint components are not detailed in the abstract, limiting interpretability from this summary alone.","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00681-4","tag_type":"warning","value":"Sample size differs by randomized (n=447) vs treated (mITT, n=442); the tag reflects the treated population used for primary analysis.","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00681-4","tag_type":"warning","value":"Study is open-label and non-inferiority; classification presented as a randomized controlled trial.","value_numeric":null}],"summaries":{"what_studied":"An open-label, multicountry, non-inferiority randomized trial compared bictegravir/emtricitabine/tenofovir alafenamide with darunavir/cobicistat/emtricitabine/tenofovir alafenamide for 48 weeks in therapy‑naive adults with advanced HIV disease (median baseline CD4 41 cells/μL). The primary endpoint was time to first specified virological or clinical event, analyzed in modified intention‑to‑treat (mITT) and per‑protocol populations.","key_result":"By 48 weeks (mITT), the composite primary event occurred in 49/220 (22%) with the integrase regimen vs 70/222 (32%) with the boosted protease inhibitor regimen (adjusted HR 0.70, 95% CI 0.48–1.00; non‑inferiority shown). Drug‑related adverse events grade ≥2 were 16/220 (7%) vs 32/222 (14%) (p=0.043); serious adverse events and discontinuations were similar, and there were 12 deaths (9 vs 3), none related to study drugs.","limitations":"Open‑label design. Follow‑up limited to 48 weeks.","practice_takeaway":"In advanced HIV disease, bictegravir/emtricitabine/tenofovir alafenamide was non‑inferior to darunavir/cobicistat/emtricitabine/tenofovir alafenamide and had fewer drug‑related adverse events over 48 weeks, supporting its use as a preferred first‑line regimen in this setting."}}],"initialOffset":5,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"generic","value":"tenofovir alafenamide"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Generics","href":"/hub/tag/generic"},{"name":"tenofovir alafenamide"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"generic","hub_tag_value":"tenofovir alafenamide"}}}]]

Papers